The Asia Pacific Non-invasive Prenatal Testing (NIPT) Market would witness market growth of 19.1% CAGR during the forecast period (2023-2030).
Prenatal care has undergone a revolutionary change due to non-invasive prenatal testing (NIPT), which has changed how expectant parents and medical professionals screen for chromosomal and genetic diseases in unborn babies. This non-invasive, highly accurate, and early screening method has gained remarkable traction in recent years, significantly impacting the landscape of prenatal testing and maternal healthcare. NIPT has witnessed widespread adoption, exhibited remarkable application in identifying foetal abnormalities, demonstrated notable trends, and seen continuous innovation, thus promising a brighter future for prenatal care.
NIPT offers a higher level of accuracy compared to traditional prenatal screening methods. It can detect a wide range of chromosomal abnormalities with a lower false-positive rate, giving parents more confidence in the results. Contrary to invasive treatments like amniocentesis or chorionic villus sampling (CVS), NIPT is non-invasive and provides little risk to the mother and the foetus. This considerably lowers the possibility of issues and miscarriages brought on by invasive testing.
The Chinese government's commitment to achieving universal healthcare coverage and reducing healthcare disparities has sparked significant investments in healthcare access and infrastructure development. China has implemented a comprehensive health insurance system, the most well-known being the New Rural Cooperative Medical Scheme (NRCMS) and the Urban Employee Basic Medical Insurance (UEBMI). Owing to the rise in healthcare spending in the Asia Pacific region, the demand for these will increase in the region.
The China market dominated the Asia Pacific Non-invasive Prenatal Testing (NIPT) Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,236.2 Million by 2030. The Japan market is registering a CAGR of 18.3% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 19.8% during (2023 - 2030).
Based on Product, the market is segmented into Consumables & Reagents, and Instruments. Based on Application, the market is segmented into Trisomy, Microdeletion Syndrome, and Others. Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics. Based on Technology, the market is segmented into Next Generation Sequencing (NGS), Microarray, Polymerase Chain Reaction (PCR), and Rolling Circular Amplification. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Global Non-invasive Prenatal Testing (NIPT) Market is Predict to reach USD 17.7 Billion by 2030, at a CAGR of 18.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Illumina, Inc., Natera Inc., F. Hoffmann-La Roche Ltd., PerkinElmer, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific SE, Thermo Fisher Scientific, Inc., GE HealthCare Technologies, Inc., Agilent Technologies, Inc., and Pacific Biosciences of California, Inc.
By Product
By Application
By End User
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
